CDCA1 epitope peptides and vaccines containing the same
Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
1. An isolated peptide of less than 15 amino acids having cytotoxic T lymphocyte (CTL) inducibility, wherein the peptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 4, 11, 14, 22 and 23, in which 1 or 2 amino acids are substituted wherein the substitution(s) is/are selected from following (a) and (b):
(a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 3, 4, 11, 14, 22 or 23 is substituted with an amino acid selected from the group consisting of phenylalanine, tyrosine, methionine and tryptophan, and
(b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 3, 4, 11, 14, 22 or 23 is substituted with an amino acid selected from the group consisting of phenylalanine, leucine, isoleucine, tryptophan and methionine.
2. The isolated peptide of claim 1 , wherein the peptide is a nonapeptide or decapeptide.
3. A composition comprising at least one peptide of less than 15 amino acids having CTL inducibility, wherein the peptide comprises an amino acid sequence selected from the group consisting of:
(a) SEQ ID NOs: 3, 4, 11, 14, 22 and 23; and
(b) SEQ ID NOs: 3, 4, 11, 14, 22 and 23, in which 1 or 2 amino acids are substituted, wherein the substitution(s) is/are selected from following (I) and (II)
(I) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 3, 4, 11, 14, 22 or 23 is substituted with an amino acid selected from the group consisting of phenylalanine, tyrosine, methionine and tryptophan, and
(II) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 3, 4, 11, 14, 22 or 23 is substituted with an amino acid selected from the group consisting of phenylalanine, leucine, isoleucine, tryptophan and methionine,
as an active ingredient in combination with a pharmaceutically acceptable carrier and an adjuvant,
wherein the pharmaceutically acceptable carrier is sterilized water, physiological saline or phosphate buffer.
4. The composition of claim 3 , wherein the composition comprises a peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4, 11, 14, 22 and 23.